TrialGut2012

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Wolfgang Hueber et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.